Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Anaemia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Anaemia
    FDA Approves Ferumoxytol for Iron Deficiency Anaemia in Patients With CKD - (DGNews)
    TopAbstracts in Anaemia 06/24/2009 - (DGNews)
    TopAbstracts in Anaemia 06/10/2009 - (DGNews)
    Use of Mycophenolate Mofetil Associated With Pure Red Cell Aplasia, Warns Health Canada - (DGNews)
    Once-Monthly Continuous Erythropoietin Receptor Activator Safe Switch for Managing Anaemia in Renal Transplant Patients Taking Erythropoiesis Stimulating Agents: Presented at ATC - (DGDispatch)

    News archive

     Recent webcasts/CME - Anaemia
    Assuring the Safe and Appropriate Management of Anemia in Two Patient Populations: Cancer and Chronic Kidney Disease
    Anemia Following Roux-en-Y Surgery for Morbid Obesity: A Review

    Webcasts/CME archive

     Recent cases - Anaemia
      Laryngeal Manifestations of Haemochromatosis
      Acute Myocardial Infarction and Pulmonary Embolism in a Young Man with Pernicious Anemia-Induced Severe Hyperhomocysteinemia
      Hook Worm Caused Chronic Anemia Found During the Procedure of Acute Gastrointestinal Bleeding: A Case Report
      Idiopathic Autoimmune Hemolytic Anemia Due to Lecithin Overdose: A Case Report
      The First Description of Severe Anemia Associated with Acute Kidney Injury and Adult Minimal Change Disease: A Case Report

      Cases archive
        




      my personal edition > anaemia > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Once Weekly Epoetin Beta Regimen Effectively Treats Chemotherapy-Induced Anaemia

      A DGReview of :"Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production"
      British Journal of Haematology

      08/08/2003
      By Jill Taylor


      Epoetin beta given once weekly is an effective and safe treatment for anaemia in patients with lymphoproliferative malignancy and defective endogenous erythropoietin production, say Italian researchers.

      The guidelines of the American Society of Clinical Oncology and the American Society of Haematology recommend epoetin as a treatment option for patients having chemotherapy-associated anaemia (Hb <10 g/dL) and advise subcutaneous administration of 150 U/kg three times weekly.

      In a previous uncontrolled, non-randomised community-based study, results indicated that epoetin alpha administered at 40,000 IU produced therapeutic effects similar to a conventional regimen. Because a once-weekly regimen offers potential cost savings, Mario Cazzola, MD, Division of Haematology, IRCCS Policlinico S. Matteo, Pavia and colleagues conducted a prospective, randomised trial to compare the efficacy of once weekly and thrice weekly regimens.

      The researchers randomised a population of 241 anaemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma or chronic lymphocytic leukaemia, to receive epoetin beta once weekly (119 patients, 30 000 IU dosage) or three times weekly (122 patients, 10 000 dosage) over 16 weeks.

      Epoetin beta was administered by patients using the RecoPenŽ (F. Hoffmann-La Roche) subcutaneous self-injection delivery system. Dosage was doubled for patients in either regimen group who failed to respond to therapy after 4 weeks. For patients responding with an Hb increase greater than 2 g/dL within 4 weeks, the dosage was reduced by half.

      The primary efficacy criterion was the time-adjusted area under the Hb-time curve (Hb AUC5-16), which showed that the once weekly regimen was clinically comparable to the thrice-weekly regimen [difference = - 0.20 g/dL (90% confidence interval - 0.52-0.11)].

      Furthermore, therapeutic response rates were high and similar in both groups (72% in the once weekly regimen and 75% in the thrice-weekly regimen).

      Data also showed that lower serum erythropoietin was associated with greater likelihood of treatment response (P = 0.002), indicating predictive value of baseline serum erythropoietin.

      "Tailoring this treatment modality to subjects with defective endogenous Epo production represents a rational use of epoetin from both a medical and a community perspective," the researchers conclude.

      The study was promoted and supported by F. Hoffmann-La Roche Ltd., Basel, Switzerland.
      Br J Haematol 2003 Aug;122:3:386-393. "Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send